Potential Implications of Expanded FDA Labeling for Sacubitril/Valsartan
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US
JAMA Cardiol 2021 Sep 15;[EPub Ahead of Print], M Vaduganathan, BL Claggett, SJ Greene, R Aggarwal, AS Bhatt, JJV McMurray, GC Fonarow, SD SolomonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.